In this episode of The Scalpel’s Edge, Dr. Tim Sayed breaks down compelling new research on GLP1 medications like semaglutide, tirzepatide, and the latest entrant, ecnoglutide. With real-world data from Cleveland Clinic and insights from an international Phase 3 trial, Dr. Sayed explores how these medications are performing outside of clinical trials, what happens after patients stop taking them, and why cost, side effects, and genetic profiles may impact their effectiveness. As a board-certified plastic surgeon who has personally used these medications, Dr. Sayed shares clinical insight, practical considerations, and where innovation in weight loss treatment is headed next. If you're curious about the future of GLP1s, their metabolic benefits, and what it means for real patients, this one’s for you.Contact Dr. Tim Sayed:Phone: (858) 247-2933Email: [email protected]: timsayedmd.comInstagram: @timsayedmdYouTube: @TimsayedmdFacebook: Tim Sayed MD

Ver todos los episodios